Aripiprazole, developed as a D2R partial agonist, is a widely used antipsychotic drug with fewer side effects, including extrapyramidal symptoms and metabolic disorder, than those associated with other antipsychotic drugs 23, 24. Here, DRD2 is linked to metabolic disease.